Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,701–1,800 of 2,932
Chemistry and Antifungal Activity of Homoisoflavonoids
Ferreira, A. R., & de Sousa, D. P. (2023) · Journal of Chemistry · doi:10.1155/2023/1223690 · Cited by 4
Shapiro, R. S., & Gerstein, A. C. (2023) · mBio · doi:10.1128/mbio.01073-23 · Cited by 4
Bauer, I., Bayram, Ö. S., & Bayram, Ö. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220253 · Cited by 6
Las infecciones fúngicas: una amenaza creciente
Gómez, B. L., & Escandón, P. (2023) · Biomédica · doi:10.7705/biomedica.7214 · Cited by 9
Pan, B., Weerasinghe, H., Sezmis, A. L., McDonald, M. J., Traven, A., Thompson, P. E., & Simm, C. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00199 · Cited by 5
Ni, T., Chi, X., Wu, H., Xie, F., Bao, J., Wang, J., Ji, Z., Li, L., Wang, X., Yan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116026 · Cited by 4
New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome
Palmucci, J. R., Messina, J. A., Tenor, J. L., & Perfect, J. R. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011845 · Cited by 5
Macrophages inhibit extracellular hyphal growth of A. fumigatus through Rac2 GTPase signaling
Tanner, C. D., & Rosowski, E. E. (2024) · Infection and Immunity · doi:10.1128/iai.00380-23 · Cited by 8
Nagai, K., Kobayashi, K., Miyake, R., et al. (2024) · The Journal of Antibiotics · doi:10.1038/s41429-023-00700-4 · Cited by 4
Estimated burden of fungal infections in Panama
Rodriguez-Vargas, C. M., Alastruey‐Izquierdo, A., Denning, D. W., & Araúz, A. B. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101466 · Cited by 6
“Both predisposing diseases and fungal diseases continue to increase over the last years [1].”
BackgroundSelf-citationXu, Z.-C., Ma, X.-R., Zhang, L., Chen, H., Qing, D.-M., Li, R., Ye, R., & Wang, R. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112522 · Cited by 4
Aspergillus-associated diseases from an infectious diseases and allergological perspective
Stemler, J., Nacov, J. A., Sprute, R., Cornely, O. A., Joest, M., Becker, S., & Klimek, L. (2024) · Allergo Journal International · doi:10.1007/s40629-024-00286-9 · Cited by 7
“The estimated annual incidence is currently over 300,000 cases worldwide [18].”
Nguyen, K. N., Freeman, L. M., Ung, T. H., et al. (2024) · Journal of Neurosurgery Case Lessons · doi:10.3171/case23672 · Cited by 4
Rethinking Aspergillosis in the Era of Microbiota and Mycobiota
Barac, A. M., Vujović, A., Perić, J., Tulić, I., Stojanović, M., & Stjepanović, M. (2024) · Mycopathologia · doi:10.1007/s11046-024-00853-2 · Cited by 6
“IPA is estimated to affect around 300.000 patients annually [1, 20].”
InfluentialSilva, S. D. M., Echeverri, C. R., Mendes‐Giannini, M. J. S., Fusco‐Almeida, A. M., & González, Á. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100246 · Cited by 6
“Paracoccidioidomycosis (PCM) is geographically localized in the Americas, affecting over 4000 people annually, although these numbers do not accurately reflect the reality due to the lack of compulsory disease reporting in most countries (Bongomin et al., 2017).”
BackgroundFungal photoinactivation doses for UV radiation and visible light–a data collection
Gierke, A.-M., Vatter, P., & Heßling, M. (2024) · AIMS Microbiology · doi:10.3934/microbiol.2024032 · Cited by 4
Fungal Extracellular Vesicle Proteins with Potential in Biological Interaction
Xu, J., Zhao, Y., Zhou, Y., Dai, S., Zhu, N., Meng, Q., Fan, S., Zhao, W., & Yuan, X. (2024) · Molecules · doi:10.3390/molecules29174012 · Cited by 7
Antifungal Efficacy of Plant Essential Oils Against Candida, Aspergillus and Cryptococcus Species
Kumari, K. M. U., Imam, M. W., & Luqman, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5165-5_5 · Cited by 4
Alsowaida, Y. S., Sulaiman, K. A. A., Mahrous, A. J., Alharbi, A. A., Bifari, N., Alshahrani, W. A., Almangour, T. A., Damfu, N., Banamah, A. A., Raya, R. R. A., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107234 · Cited by 4
Fungal Attachment-Resistant Polymers for the Additive Manufacture of Medical Devices
Yong, L. X., Sefton, J., Vallières, C., Rance, G. A., Hill, J., Crucitti, V. C., Dundas, A. A., Rose, F. R. A. J., Alexander, M. R., Wildman, R. D., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c04833 · Cited by 4
Ranjan, K., Morais, J. A. V., Dixit, M., Nunes, L. C., Rodrigues, F. P., Muehlmann, L. A., Shukla, P., & Poças-Fonseca, M. J. (2024) · Lasers in Medical Science · doi:10.1007/s10103-024-04204-x · Cited by 4
“Mucorales , Aspergillus , Candida , and Cryptococcus species are frequent pathogens [2, 3].”
Yu, Y., Vogel, T., Hirsch, S., Gröll, J., Albrecht, K., & Beilhack, A. (2024) · Nanoscale · doi:10.1039/d4nr03225j · Cited by 5
Bitencourt, T. A., Nogueira, F., Jenull, S., Phan-Canh, T., Tscherner, M., Kuchler, K., & Lion, T. (2024) · Communications Biology · doi:10.1038/s42003-024-07145-x · Cited by 7
Gao, N., Fang, C., Bai, P., Wang, J., Dong, N., Shan, A., & Zhang, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137894 · Cited by 4
Bende, G., Zsindely, N., Laczi, K., Kristóffy, Z., Papp, C., Farkas, A., Tóth, L., Sáringer, S., Bodai, L., Rákhely, G., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01273-24 · Cited by 6
Paul, R. A., Madduri, M., Kashyap, N., Ramesh, S., Rudramurthy, S. M., & Roy, U. (2024) · Apmis · doi:10.1111/apm.13506 · Cited by 7
“Candida albicans , Cryptococcus neoformans , and Aspergillus fumigatus are the predominant fungal pathogens that cause life-threatening invasive infections, often but not exclusively in immunocompromised patients [1].”
Biomass Carbon Dots: Illuminating New Era in Antimicrobial Defense and Cancer Combat
Jose, S., Anaswara, K. P., Mathew, A. A., Varghese, M., & Balachandran, M. (2025) · BioNanoScience · doi:10.1007/s12668-024-01686-5 · Cited by 7
Current strategies in design and synthesis of antifungals hybrid and chimeric diazine derivatives
Diaconu, D., Savu, M., Ciobanu, C. I., Mangalagiu, V., & Mangalagiu, I. I. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118069 · Cited by 10
Mycobiome: an underexplored kingdom in cancer
Sun, Y.-Y., & Liu, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00261-24 · Cited by 5
“An estimated 6.55 million individuals get potential fatal fungal infections annually, and 3.75 million people die from fungal diseases, which are thought to affect over 1 billion people annually (13, 14).”
InfluentialRao, R. S. P., Pinto, L., Suravajhala, R., Shenoy, B. D., Sashindran, V. K., & Ghate, S. D. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2479847 · Cited by 4
“They are estimated to be responsible for around 1.5 million deaths per year (Bongomin et al., 2017).”
InfluentialMeng, X., Liu, X., Li, L., Zheng, D., Zeng, L., Liu, Y., Li, R., Zhu, M., Cao, C., Cao, X., et al. (2025) · Mycopathologia · doi:10.1007/s11046-025-00940-y · Cited by 4
“There are significant geographical differences in the distribution of IFD pathogenic fungi worldwide [14].”
Development of a novel family of antifungal agents based on a quinone methide oxime framework
Janeczko, M., Masłyk, M., Demchuk, O. M., Kurowska-Okoń, A., Kwaśnik, M., Górka, K., Martyna, A., Josselin, B., Ruchaud, S., Bach, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98609-5 · Cited by 6
“%) despite the use of antifungal therapy 10,11 .”
Zheng, L., Dong, Y., Wang, J., Jia, Y., Wang, W., Xu, Y., & Guo, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1519323 · Cited by 7
Uncovering the antifungal potential of Cannabidiol and Cannabidivarin
Dinh, H., Fernandes, K. E., Erpf, P. E., Clay, E. J. M., Tay, A. P., Nagy, S. S., Schaefer, S., Maharjan, R. P., Lenardon, M. D., Multari, D. H., et al. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0013081 · Cited by 5
Incidence and clinical outcome of Cryptococcosis in a nation with advanced HIV surveillance program
Abid, F. B., Soub, H. A. R. S. A., Maslamani, M. A. R. S. A., Ibrahim, W. H., Ghazouani, H., Al‐Khal, A., & Taj‐Aldeen, S. J. (2019) · The Aging Male · doi:10.1080/13685538.2019.1692198 · Cited by 4
“Latex agglutination test or enzyme-linked immunosorbent assay (ELISA) rarely misses positive cases with the exception of cases with very early disease or in those with very high titers due to the prozone effect [21].”
BackgroundCandidiasis invasora: un enfoque a la infección en el sistema nervioso central
Vigezzi, C., Riera, F. O., Rodríguez, E., Icely, P. A., Miró, M. S., Figueredo, C. M., Caeiro, J. P., & Sotomayor, C. E. (2020) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2020.06.003 · Cited by 10
Ansari, M. J., Ahmed, M. M., Anwer, M. K., et al. (2020) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2020/v32i2930892 · Cited by 4
In silico designing of some Benzimidazole derivatives for Anti-fungal activity
Muralikrishnan, A., Nair, R. R., Banu, J. N., & Pappachen, L. K. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00867 · Cited by 4
Echinocandin Drugs Induce Differential Effects in Cytokinesis Progression and Cell Integrity
Yagüe, N., Gómez-Delgado, L., Curto, M.-Á., Carvalho, V. S. D., Moreno, M. B., Pérez, P., Ribas, J. C., & Cortés, J. C. G. (2021) · Pharmaceuticals · doi:10.3390/ph14121332 · Cited by 4
“6 million people die each year because of severe fungal infections [1,4].”
BackgroundOhnishi, Y. D. O., Pantoja, A. S. L., Abraão, L. S. D. O., et al. (2022) · Revista Pan-Amazônica de Saúde · doi:10.5123/s2176-6223202200950 · Cited by 4
Starodubtseva, M. N., Karachrysafi, S., Shkliarava, N. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810464 · Cited by 4
“The frequency of fungal infections is increasing every year, which is a significant medical and social problem worldwide [1].”
BackgroundWhat do We Have That is New in Antifungal Peptides? A Patent Review
Zambrano, P., Xavier, L. D. C., Santos, A. M., Rossato, L. L., da Costa, J. D. C., Serafini, M. R., Aragón, M., Souto, R. B., & Alves, I. A. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0105 · Cited by 5
Schulz, J., Michelet, R., Zeitlinger, M. A., Mikus, G., & Kloft, C. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03407-7 · Cited by 5
Rai, M. N., Parsania, C., & Rai, R. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105864 · Cited by 4
Exploring Cryptococcus neoformans CYP51 and Its Cognate Reductase as a Drug Target
Ruma, Y. N., Keniya, M. V., & Monk, B. C. (2022) · Journal of Fungi · doi:10.3390/jof8121256 · Cited by 5
HAKOBYAN, H. (2022) · FARMACIA · doi:10.31925/farmacia.2022.6.19 · Cited by 4
Identification of Candida Species Isolated from Hospitalized Patients with Candiduria
Moazeni, M., & Nabili, M. (2022) · شهباز. · doi:10.61186/mlj.16.2.13 · Cited by 9
Mehta, S. A., Gupta, K., & Nakshiwala, N. P. (2023) · Cureus · doi:10.7759/cureus.43508 · Cited by 4
Phaeohyphomycosis caused by Corynespora cassiicola , a plant pathogen worldwide
Hu, D., Jiang, W., Zhu, X., Hou, Q., Chen, M., Xue, X., Zhao, J., İlkit, M., Arastehfar, A. A., Fang, W., et al. (2023) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2023.2247433 · Cited by 4
“However, advancements in clinical intervention (immunosuppression, transplantation, chemotherapeutic drugs, etc.) (Bongomin et al. 2017), the increasing number of patients identified with in-born genetic deficiencies (Lanternier et al. 2015) and sprawling human habitats to vegetative areas, where…”
BackgroundLatin American Plants against Microorganisms
Cuevas-Cianca, S. I., Romero-Castillo, C., Gálvez-Romero, J. L., Sánchez-Arreola, E., Juárez, Z. N., & Hernández, L. R. (2023) · Plants · doi:10.3390/plants12233997 · Cited by 7
“…to take into account that mycosis can be considered dangerous due to the entry of several fungi, with cosmopolitan genera such as Candida , Cryptococcus , and Aspergillus being prevalent [63–65], while creating invasive fungal infections (IFIs) that cause high mortality rates worldwide [60,66,67].”
BackgroundPeixoto-Rodrigues, M. C., da Costa, G. L., Pinto, T. N., Adesse, D., Oliveira, M. M. E., & Hauser‐Davis, R. A. (2023) · BMC Microbiology · doi:10.1186/s12866-023-03128-w · Cited by 5
“…particularly among high-risk populations such as individuals with HIV/ AIDS, transplant recipients, and those with weakened immune systems [42–44], although certain fungi, including Cryptococcus , Coccidioides , and Histoplasma , can also infect people with healthy immune systems [45–47].”
BackgroundBiçer, M. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03744-0 · Cited by 6
“The prevalence of fungal infections induced by pathogenic fungi has experienced a significant increase globally, resulting in a considerable number of annual deaths (Bongomin et al. 2017; Rokas 2022).”
BackgroundSalmanton‐García, J., Koehler, P. A., Grothe, J. H., Mellinghoff, S. C., Sal, E., Simon, M., Stemler, J., Cornely, O. A., & Sprute, R. (2024) · Mycopathologia · doi:10.1007/s11046-023-00822-1 · Cited by 4
“The field of medical mycology has become increasingly vital in response to the rising prevalence of invasive fungal infections (IFI) and their impact on global health [1].”
BackgroundOtterdijk, S. V., Motealleh, M., Wang, Z., Visser, T. D., Savakis, P., & Tutucci, E. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3766-1_2 · Cited by 5
Acid- and base-resistant antimicrobial hydrogels based on polyoxometalates and chitosan
McWilliams, C., Castillo, I. F., Seral‐Ascaso, A., García-Embid, S., Malefioudaki, M., Meier, J. G., Martín‐Rapún, R., & Mitchell, S. G. (2024) · RSC Pharmaceutics · doi:10.1039/d4pm00062e · Cited by 4
Pantić, N., Barac, A. M., Mano, Dedeić-Ljubović, A., Malkodanski, I., Jakšić, O., Gkentzi, D., Mitrović, M., Munteanu, O., Šišević, D., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.102493 · Cited by 4
Wang, L., He, Z., Guo, Y., 冉向阳, Cheng, Y., & He, Z. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04899-4 · Cited by 4
“The significance of these infections lies in their potential to cause severe morbidity and mortality, comparable to that caused by tuberculosis and exceeding the impact of malaria by over three times [5, 6].”
Molecular Diagnosis of Invasive Aspergillosis
Reyes-Montes, M. D. R., Duarte-Escalante, E., León, M. G. F.-D., Martínez-Herrera, E. O., & Acosta‐Altamirano, G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.78694 · Cited by 4
“[70] estimate approximately 250,000 cases that occur worldwide each year, with an associated increase in morbidity and mortality rates.”
BackgroundEpidemiology of Opportunist Fungal Infections in Asia
Chakrabarti, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_4 · Cited by 6
Applications of Nanometals in Cutaneous Infections
Nakazato, G., Lonni, A. A. S. G., Panagio, L. A., de Camargo, L. C., Gonçalves, M. C., Reis, G. F., Miranda-Sapla, M. M., Tomiotto‐Pellissier, F., & Kobayashi, R. K. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-35147-2_4 · Cited by 9
Rybalkin, M. V., Стрельников, Л. С., Стрілець, О. П., Калюжная, О. С., & Kutsenko, S. (2020) · Chemistry & Chemical Technology · doi:10.23939/chcht14.04.455 · Cited by 4
Airborne fungi in Universiti Sains Malaysia: knowledge, density and diversity
Xin, T. K., Azman, N. M., Firdaus, R. B. R., Ismail, N. A., & Rosli, H. (2021) · Environmental Monitoring and Assessment · doi:10.1007/s10661-021-09238-0 · Cited by 6
Sariyanti, M., AGUSTRIA, P. M., HERLAMBANG, W. F., Sinuhaji, B., Wıbowo, R. H., LESTARI, N., Nugraheni, E., & Sipriyadi, S. (2021) · Microbiology Indonesia · doi:10.5454/mi.15.1.4 · Cited by 6
“The current (Bongomin 2017)et al. report from 14 countries, 12.5% of the global population were affected by fungal disease (Denning 2017).”
InfluentialRecent trends in the development of bacterial and fungal vaccines
Mir, M. A., Usman, M., Qadri, H., & Aisha, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96127-1.00003-6 · Cited by 5
Alonso, M. F., Bain, J. M., Rudkin, F. M., Erwig, L. P., Brown, A. J. P., & Gow, N. A. R. (2022) · The Cell Surface · doi:10.1016/j.tcsw.2022.100082 · Cited by 5
“Aspergillus and Pneumocystis although infections caused by members of the order Mucorales are also frequently reported (Bongomin et al., 2017; Brown et al., 2012) and are often associated with various co-morbidities (Raut, 2021; Hoenigl et al., 2022).”
BackgroundChallenges in Invasive Fungal Disease
Chakrabarti, A., & Singh, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-9349-5_18 · Cited by 4
Qin, Y., Lu, Y., Zhou, Y., Harypursat, V., Sun, F., Yang, S., Tang, S., Li, Y., He, X., Zeng, Y., et al. (2020) · Trials · doi:10.1186/s13063-020-04450-8 · Cited by 4
Fungal Melanin Rewires Macrophage Metabolism
Papon, N., Gangneux, J., & Delneste, Y. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.006 · Cited by 4
Aldossary, S., & Shah, A. (2021) · Mycopathologia · doi:10.1007/s11046-021-00547-z · Cited by 4
“Aspergillus-related disease also affects * 20% of individuals with cystic fibrosis (CF), leading to increased exacerbation frequency [3].”
BackgroundAntifungal Drugs Loaded Nanosponges to Improve Bioavailability of Antifungal Drugs; A Review
Shahzad, Q. (2021) · Open Access Journal of Pharmaceutical Research · doi:10.23880/oajpr-16000255 · Cited by 5
van Rhijn, N., Hemmings, S., Valero, C., Amich, J., & Bromley, M. (2021) · Research Square · doi:10.21203/rs.3.rs-1079988/v1 · Cited by 4
“Introduction: 33 Invasive and chronic forms of aspergillosis affect over 3 million people resulting in excess of 34 300 thousand deaths per year [1].”
BackgroundSeyedmousavi, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc295 · Cited by 4
Washington, E., Zhou, Y., Hsu, A. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.14.530545 · Cited by 4
“3 Introduction 54 Invasive fungal diseases (IFDs) caused by pathogenic fungi such as Cryptococcus, 55 Candida and Aspergillus are a major threat to human health, resulting in more than one and a 56 half million deaths worldwide each year (1, 2).”
Epidemiology of Histoplasmosis
Efrim, N. D., Dumea, E., & Cernat, R. C. (2023) · Infectious diseases · doi:10.5772/intechopen.110901 · Cited by 9
Bansal, S. B., Kher, V., Ramsubramanian, V., et al. (2022) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_106_21 · Cited by 3
Invasive Fungal Infections of the Head and Neck: A Tertiary Hospital Experience
Hou, T., Bell, W. R., & Mesa, H. A. (2024) · Pathogens · doi:10.3390/pathogens13070530 · Cited by 3
“The incidence of invasive fungal disease has been rising; recent assessments show that globally, every year, more than 150 million people suffer from serious infections and more than 1.6 million die of invasive mycoses [3].”
BackgroundInfluentialJia, S., Zhu, J., Zhou, Z., Luo, W., Shang, Z., Jiang, Y., Tsui, C. K. M., Che, D., & Jiang, Y. (2025) · Mycopathologia · doi:10.1007/s11046-024-00922-6 · Cited by 5
“A wealth of data has demonstrated that socio-economic conditions are associated with the prevalence of dermatophytosis [2, 3, 6, 27].”
Chen, Y., Zhao, J., Wang, Y., Ge, L., Kwong, J. S.-W., Lan, J., Zhang, R., Zhao, H., Hu, L., Wang, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1530999 · Cited by 5
Bugeda, A., Shi, X., Castillo, L., Marcos, J. F., Manzanares, P., López‐Moya, J. J., & Coca, M. A. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70093 · Cited by 4
“Fungal infections can range in severity from mild to life-threatening, even surpassing death rates from well-known parasitic organisms such as Malaria (Bongomin et al ., 2017).”
Design, synthesis and biological evaluation of natural product echinocandin derivatives
Chu, S., Zheng, Y., Wang, G., Su, S., Wang, H., Chen, S., & Wu, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117896 · Cited by 3
Schiele, A., Timofeev, S. M., Mota, A., & Cortesão, M. (2025) · International Journal of Astrobiology · doi:10.1017/s147355042510013x · Cited by 3
“Moreover, fungal pathogens can physically invade and colonise host organisms, causing fungal biofilms on mucous membranes with varying severity, particularly in immunocompromised individuals (Bongomin et al ., 2017).”
Fungal communities in split air conditioners and associated health risks
Liu, Y., Wang, Z., Li, X., Xu, Z., Yang, Y., Wang, Z., Li, Q., & Zhan, B. (2025) · Building and Environment · doi:10.1016/j.buildenv.2025.113557 · Cited by 4
Hidden Allies: Decoding the Core Endohyphal Bacteriome of Aspergillus fumigatus
Piontkivska, D., Jorge, J. M. P., Mil‐Homens, D., Martins, T. M., Crespo, P., Morales, D., Carvalho, D., Melo‐Cristino, J., Sá‐Leão, R., Goldman, G. H., et al. (2025) · Environmental Microbiology Reports · doi:10.1111/1758-2229.70153 · Cited by 4
“…new estimates indicate that over 6.5 million people are affected by invasive fungal infections and chronic pulmonary aspergillosis, with an overall crude mortality of nearly 3.8 million, of which 68% corresponds to the attributed mortality (Firacative 2020; Bongomin et al. 2017; Denning 2024).”
InfluentialRhodes, J. L. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_327 · Cited by 6
Huang, Y., Song, N., Jing, D., Liu, W., Li, D., Zhou, X., & Li, X. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00810-25 · Cited by 4
Singh, T., Vikal, A., Patel, P., Gupta, G. D., Thakur, S., & Kurmi, B. D. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03261-x · Cited by 5
“Superficial fungal infections are particularly prevalent, with an estimated global incidence of 20% to 25% [1–4].”
Eknure, C., Agarwal, A. P., Bachhav, Y. G., & Kumar, M. S. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04671-6 · Cited by 5
Ghosh, S., Rahaman, S. M., Ghosh, N. G., et al. (2026) · New Journal of Chemistry · doi:10.1039/d5nj04411a · Cited by 3
Burn Infections and Sepsis: Challenges and Future Prospects of Antibacterial Therapy
Dadashizadeh, G., Elloso, M. S., & Jeschke, M. G. (2026) · Antibiotics · doi:10.3390/antibiotics15040383 · Cited by 4
Calvi, G. D. S., Braga, M. T., Cartaxo, G. N. J., Kubát, P., Liška, V., Mosinger, J., & Costa, M. S. (2026) · ACS Omega · doi:10.1021/acsomega.5c08078 · Cited by 3
Salah, H., Kolecka, A., Rozaliyani, A., Wahyuningsih, R., Taj‐Aldeen, S. J., Boekhout, T., & Houbraken, J. A. M. P. (2022) · Mycopathologia · doi:10.1007/s11046-021-00603-8 · Cited by 3
“5 million deaths worldwide, especially in immunocompromised individuals [1].”
BackgroundThioterpenoids of the Bornane Series with Potent Activity Against Opportunistic Micromycetes
Nikitina, L. E., Lisovskaya, S. А., Gilfanov, I. R., Pavelyev, R. S., Ostolopovskaya, O. V., Fedyunina, I. V., Kiselev, S. V., Azizova, Z. R., Pestova, S. V., Изместьев, Е. С., et al. (2023) · BioNanoScience · doi:10.1007/s12668-023-01069-2 · Cited by 3
“The number of mycoses caused by opportunistic micromycetes increases by 5–10 % yearly and doubles every 10 years [1].”
BackgroundSingha, R., Aggarwal, R., & Sanyal, K. (2023) · Molecular Microbiology · doi:10.1111/mmi.15050 · Cited by 3
“…of the oral cavity, gastrointestinal tract, and genitourinary regions, but is also one of the most frequently isolated fungal species in patients diagnosed with candidemia or other nosocomial Candida infections (Bongomin et al., 2017; Brown et al., 2012; Odds, 1987; Pfaller & Diekema, 2007).”
BackgroundRegulation of Surfactant Protein Gene Expression by Aspergillus fumigatus in NCl-H441 Cells
Schiefermeier-Mach, N., Heinrich, L., Lechner, L., & Perkhofer, S. (2023) · Microorganisms · doi:10.3390/microorganisms11041011 · Cited by 3
“Despite current therapy, the mortality of pulmonary aspergillosis is reported to reach 30% to 80% [5].”
BackgroundPhysicians' knowledge of invasive fungal disease in China
Chen, Y., Huang, X., Qiu, H., et al. (2023) · Mycoses · doi:10.1111/myc.13590 · Cited by 3
Fu, M. S., Kawakami, K., & Drummond, R. A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3199-7_7 · Cited by 2
Antifungal compounds: With special emphasis on echinocandins, polyenes, and heterocyclic benzofurans
Devi, D. S., Bose, M., & Dass, R. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95388-7.00009-7 · Cited by 4
Fakhim, H., Vaezi, A., Morovati, H., Bandegani, A., Abbasi, K., Emami, S., Nasiry, D., Hashemi, S. M., Ahangarkani, F., & Badali, H. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101437 · Cited by 3
Streptomyces: a natural source of anti-Candida agents
Martins, N. D. R. C., da Silva, A. R., Ratcliffe, N. A., Evangelho, V. G. O., Castro, H. C., & Quinn, G. A. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001777 · Cited by 6
Micelly-Moreno, J., Barreto-Santamaría, A., Arévalo‐Pinzón, G., Firacative, C., Gómez, B. L., Escandón, P., Patarroyo, M. A., & Muñoz, J. E. (2023) · Journal of Fungi · doi:10.3390/jof9121149 · Cited by 5
“Globally, invasive candidiasis is the most frequent mycosis, causing nearly 750,000 cases per year, with a mortality rate close to 40% [2,3].”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.